Date post: | 28-Mar-2015 |
Category: |
Documents |
Upload: | darryl-sinden |
View: | 214 times |
Download: | 1 times |
Causes of Fatigue in Patients with Heart Failure
Donna Mancini, MD
Columbia University
New York, NY
Symptoms of CHF
• Fatigue
• Dyspnea
Fatigue in HF• Impaired Cardiac Output Response with Skeletal
Muscle Hypoperfusion• Abnormal Vasodilation/Altered Endothelial Fn• Skeletal Muscle Dysfunction• Malnutrition/Cachexia• Cytokine Activation• Anemia• Depression• Sleep apnea• Medications (ß blockers; overdiuresis)
Non-Cardiac CoMorbidities in Patients >65 yrs with CHF (n=122,630)
• Essential HT- 55%• HT w complications-11%• Diabetes-31%• COPD-26%• Other respiratory disorders-
11%• Asthma-5%• Ocular Disorders-24%• Hypercholesterolemia-21%
• Osteoarthritis-16%• Osteoporosis-5%• Alzheimer’s-9%• Depression-8%• Anxiety-3%• Chronic Renal Failure 7%• Renal Insufficiency-4%• PVD-16%• Thyroid 14%• Cerebrovascular Disease-3%
Braunstein, JACC 2003;42: 1793
Padeletti, Sleep Medicine 2008;1132
• CHF associated with Central and ObstructiveSleep Apnea in up
to 40% of stable HF pts
• 28 of 29 patients admitted with acute decompensated CHF had SDB
• Patients with SDB have lower peak VO2 vs those without
• Interventions associated with increase in VO2 such as CRT are also associated with decrease in SDB
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Cheyne Stokes- Central Sleep Apnea
Elements of Fatigue
• Psychological: Mental Weariness
• Physiologic: Physical inability– Central– Peripheral
Lung Heart Muscle
VO2= O2 delivery-O2 extractionVO2= CO * (A-VO2 difference)
O2 delivery: Cardiac Output Pulmonary Function Hemoglobin Concentration
O2 Extraction: Muscle Oxidative Capacity Vasodilatory Capacity
Isokinetic Strength Testing• Maximum Voluntary
Contraction• Fatigue Index
– Duration of a sustained contraction
– Endurance: multiple repetitions
Qualitative Assessments of Fatigue
• Ratings of Perceived Fatigue -Borg Scale– Scale of 6-20 corresponds to HR response to
exercise
• Quality of Life Questionnaires
• Visual Analogue Scales
Decreased CO response
• Results in decreased skeletal muscle perfusion• Early Lactic acidosis• Fatigue
Peak Cardiac Output (L/min)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 150.0
7.4
14.8
22.2
29.6
37.0
y = 4.746119 + 1.089822 * x
r=0.64;p<0.0001
Lang Am J Cardiol 2007
Cardiac Output Response
Weber, Circ 1982;65:1215
Skeletal Muscle in CHF
• Morphological Changes (reduction in muscle mass)
• Histological Changes (shift in fiber types)
• Biochemical changes: shift from oxidative to glycolytic metabolism (31P MRS)
Muscle HypothesisMuscle as a Sensory Organ
LV dysfunction
Decreased Perfusion Increased Cytokines Decreased Activity
ExerciseMuscleAtrophic
DeconditionedMetabolically abnl
Afferents
Fatigue Breathlessness
Hypoxia
Anthropomorphic Assessement (n=62)
0
25
50
75
<5 (5-25) (25-50)
>50
Arm Muscle Circumference (% of standard)
Per
cen
t of
Pat
ien
ts
0
25
50
75
<5 (5-25) (25-50)
>50
Triceps Skin Fold (% of standard)
Per
cen
t of
Pat
ien
ts
Mancini Circ 1989;80:1338
Muscle Wasting
DEXA Scanning in CHF
Controls (n=16)
Noncachetic (N=40)
Cachetic (n=18)
Total Fat (kg)
207 228 144*
Muscle (kg) 584 576 465*
Bone (kg) 3.1.4 3.1.3 2.6.2*
Anker AJC 99:83
Mancini, Circ 1992;86:909
NL CHF
Pathogenic Factors for Cardiac Cachexia
• Generalized Cellular Hypoxia• Decreased Caloric Intake
– Anorexia from gastric and hepatic congestion– Depression
• Increased Caloric Expenditure– Increased Work of Breathing– Increased Metabolic Rate
• Iatrogenic Factors– Salt and Water Restriction– Diuretics, Cardiac Glycosides– Therapeutic Removal of body fluids
Anasari, Progress in CV Disease 1987
Histologic Changes
Type I and II Atrophy Type II b Type I oxidative enzymes mitochondria volume
ATPase stain @pH 4.6
NL CHF CHF
Mancini, Circ 1992;86:909
Mancini, Circ 1992;86:909
Enzyme ChangesFiber Type Changes
Mancini, Circ 1992;86:909
Hambrecht JACC 1997;29:1067
Hambrecht, JACC 1999;33:174
Other Skeletal Muscle Changes
• Increased apoptosis (Vescovo JMoll CellCardiol 1998)
• Oxidation of myosin (Coirault Am J Physiol 2007)
• Hyperphosphorylation of the ryanodine receptor (Wehrens PNAS Medical Sciences 2005)
• Decrease in SERCA-2
Mancini Circ 1994;90:500
Kao W, AJC 1995;76:606
PCrConcentration
ATP use &production
ATP use stopsAccelerated production continues
WORK
Start Stop
Mancini Circ 1992;85:1364
Mancini Circ 1992;85:1364
Recovery time provides an index of oxidative metabolismIndependent of muscle mass
CHFNL
Mancini Circ 1994;90:500
Reduced oxidative metabolismDespite similar oxygenation level
Chati, AHJ 1996;131:560
Coats, Circ 1992;85:2119
Mancini Circ 1992;86:909
Mancini Circ 1992;86:909
Mancini Circ 1992;86:909
Low frequency fatigue does not occur
Mancini Circ 1992;86:909TTI= (Pdi/Pdi max) * (Ti/Ttot)
Figure 1Graphic
Nl
HF
Tikunov Circ 1997;95
Tikunov Circ 1997;95
Immune Activation in CHF
• Reduced peripheral blood flow results in local ischemia and macrophage activation leading to cytokine release and endothelial dysfunction
• Neurohormonal activation
• Catabolic state
Plasma Hormones
Control (n=16)
Non-Cachetic
CHF (n=37)
Cachetic CHF
(n=16) TNF (pg/ml) 70.7 6.90.8 15.33.1†*
hGH (ng/ml) 1.10.4 0.90.3 3.81.6†*
Aldosterone (pmol/L)
27942 55277* 1039227†*
IGF-1 (nmol/L) 14811 1499 13713
* p<0.05 control vs cachetic; † control vs non cachetic
Hormonal Changes
• Sympathetic Activation
• Renin Angiotensin Activation
• GH Resistance
• Insulin Resistance
• Increased cytokines
Nutrition and Exercise
• Nutrition forms the basis for human performance
• Food nutrients provide energy and regulate physiologic processes
• Inadequate nutrition can hinder performance• Dietary Supplements may enhance
performance
Nutrient Use During Exercise
36
14 8
37
50 62
2736 30
0%
25%
50%
75%
100%
40 180 240
Exercise Duration (min)
GlucoseFFALocal
GLYCOGEN METABOLISM IN CHF
Accelerated glycogen utilization in animal heart failure models
Reduced or low normal glycogen concentration in human heart failure skeletal muscle biopsies
POSSIBLE MECHANISMS OF ABNORMAL GLYCOGEN METABOLISM IN CHF:
Reduced delivery of substrates due to reduced muscle perfusion
Hormonal abnormalities -- elevated catecholamine levels
Intrinsic alteration of skeletal muscle metabolism with increased glycolytic activity
a. deconditioning
b. inhibition of free fatty acid metabolism
PROTOCOLJACC1999;34:1807
Baseline:
Day 1: Exercise performed in fasting state 60% protein 40% fat drink provided Glycogen Depleted: Day 2: Exercise protocol repeated Slowed Glycogen Utilization: Day 8: 60% carbohydrate, 30% protein, 10% fat
drink provided Day 9: High fat breakfast (eggs, bacon, bagel) 3.5 hours later: Heparin 2000 U IV
4 hours later: exercise repeated
Exercise Protocol
Maximal: incremental bicycle exercise using 25W workloads of 3 minutes duration with measurement of respiratory gases
Submaximal: 75% of peak workload until exhaustion
Supramaximal: 133% peak workload x 1 minute followed by 2 minutes rest;
repeated until subject is unable to complete a full min of exercise
0
10
20
30
40
NORMAL CHF
BaselineDepletedSlowed
p=NS
Peak VO2
(N=7) (N=13)
Submaximal Exercise Duration
0
10
20
30
NORMAL CHF
Exe
rcis
e D
ura
tio
n (
min
)
BaselineDepletedSlowed
*
*
p<0.05 within group
Glycogen Depletion: -57 vs -12% Nl vs HFSlowed Glycogen: 18 vs 65% Nl vs HF
Anemia Is Common
in Heart Failure Patients
00 55 1515 2020 3030 4040 50504545
% of Heart Failure Patients With Anemia
1010 2525 3535
16%16%Tang (N=2009)Tang (N=2009)11
Anker, ELITE (N=3044Anker, ELITE (N=3044)217%17%
Ezekowitz, ICcodes(N=12,065)317%17%
Mozaffarian, PRAISE (N=1130)4 20%20%
22%22%Al-Ahmad, SOLVD (N=6563)5
28%28%Herzog, Medicare ICD (N=152,584)6
30%30%Horwich, UCLA CM clinic (N=1061)7
48%48%Kosiborod, Medicare (N=2281)8
1. Tang WHW, et al. ACC 2003. 2. Anker SD, et al. Circulation. 2002;106(suppl II):472.
Abstract 2335. 3. Ezekowitz JA, et al. Circulation. 2003;107:223-225. 4. Mozaffarian D, et al. J Am Coll Cardiol. 2003;41:1933-1939.
5. Al-Ahmad A, et al. J Am Coll Cardiol. 2001;38:955-62. 6. Herzog CA, et al. J Card Fail. 2002;8(suppl):S63.
Abstract 228. 7. Horwich TB, et al. J Am Coll Cardiol. 2002;39:1780-1786. 8. Kosiborod M, et al. Am J Med. 2003;114:112-119.
Prevalence varies with age, patient population, and definition of anemia.
Potential Mechanisms for Enhancing Exercise Capacity
• Increase Hemoglobin and thus increase oxygen carrying capacity
• Reduce oxidative stress and improve vasodilatory capacity
• Increase rate of Oxygen delivery
ProtocolMancini Circ 2003;107
• Randomized single blind prospective study in 27 HF patients
• 2:1 randomization – erythropoietin 5000-10,000 U SQ TIW +
ferrous gluconate 325 mg daily and folate 1 mg daily
– placebo injection of ‘Depot Epo’ (1cc normal saline)
– 3 month study or until Hct >45%
Hemoglobin in Epo Group
8
12
16
Pre-EPO Post-EPO
*P<0.001
1.8
-0.5
-3
0
3
VO
2 (m
l/k
g/m
in)
Control EPO
Change in Peak VO2
P<0.02
Change in MLHFQ
10.0
-9.8-16
0
16
Un
its
Control Epo
*P<0.03
*P<0.016 min Walk
128
-108-150
0
150
Dis
tance (f
t)
Downward SpiralDecreased COSympathetic Stimulation
Decrease SM Blood FlowVasoconstriction
InactivityCytokine Activation Muscle wasting
DeconditioningAnemia
InactivityAnorexiaDepression
More Muscle wastingDecondtioningCachexia
FATIGUE